SciELO - Scientific Electronic Library Online

 
vol.3 número1Características del síndrome metabólico en la consulta cardiológica: Grupo de estudio CARISMA (Caracterización y Análisis del Riesgo en Individuos con Síndrome Metabólico en la Argentina)Péptido natriurético cerebral en pacientes con insuficiencia cardíaca o con factores de riesgo para su desarrollo índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Bookmark


Insuficiencia cardíaca

versión On-line ISSN 1852-3862

Resumen

ECHAZARRETA, Diego F. et al. Chronic treatment with PDE-5 inhibitors in patients with advanced heart failure. Insuf. card. [online]. 2008, vol.3, n.1, pp. 16-20. ISSN 1852-3862.

Introduction. The persistent increase of pulmonary vascular resistances (PVR) in patients with advanced heart failure (AHF) is the result of pulmonary vascular endothelium dysfunction and its structural remodelling. Diminish of nitride oxide (NO) offer, and the increase of endothelins (ET) strengthen vasoconstrictors phenomenon altering the present equilibrium with the vasodilation mediators. Sildenafil (a selective inhibitor of phosphodiesterasa 5 -PDE5-) may turn into a valid way of increasing NO levels and favouring PVR decrease in patients with AHF. Material and methods. 30 patients with AHF where selected, and divided in two groups of 15 each (sildenafil and control group) with left ventricular ejection fraction (LVEF) of 31.08±3.1% in functional class (FC) III, undergoing complete pharmacological treatment, and being evaluated with 2D transtoracic echocardiogram-colour-Doppler (TCCD) in order to measure the systolic pulmonary arterial pressure (SPAP), with the 6-minute walk test (6MWT) and an ergometric test with maximal oxygen consumption (VO2) at the baseline and at the 90th day of the follow-up. Within this period the sildenafil group received an oral mean dose of the drug of 75.4±13 mg/day. Results. An improvement was shown in the sildenafil group for both functional tests: 6MWT (sildenafil group: day 0: 144.2±42.1 m vs day 90: 171.5±56.8 m p: 0.052) and in ergometric test with VO2 (sildenafil group: day 0: 11.4±1.3ml/Kg/minuto vs day 90: 12.3±1.4 ml/kg/minute; p: 0.001). A decrease in the SPAP was also seen (sildenafil group: day 0: 36.2±6.9 mm Hg vs day 90: 33.8±6.1 mm Hg; p: 0.001); also in the arterial systolic pressure -SAP- (sildenafil group: day 0: 124.6±13.2 mm Hg vs day 90: 116.2±9.5 mm Hg; p: 0.008); and in the diastolic arterial pressure -DAP- (sildenafil group: day 0: 70.8±4.9 mm Hg vs day 90: 65.3±4.3 mm Hg; p: 0.000). Conclusions. The present study shows that the administration of a mean 75.4±13 mg/day oral dose of sildenafil is safe and improves significantly the functional performance of patients with AHF.

Palabras llave : Heart failure; Pulmonary hypertension; Sildenafil; Phosphodiesterasa 5.

        · resumen en Español | Portugués     · texto en Español     · pdf en Español